potent and selective Mcl-1 PPI inhibitor

completed Ph. I in AML/MDS (IV weekly)

from NMR fragment screening and SBDD

J. Med. Chem., Nov. 4, 2020

Servier, HU + FR / Vernalis, UK

Servier selective clinical Mcl-1 protein-protein interaction (PPI) inhibitor


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks